1	Endogenous Retroelement Expression in the Gut Microenvironment of People Living with HIV-
2	1
3	
4	Nicholas Dopkins* <sup>1</sup> , Tongyi Fei <sup>1</sup> , Stephanie Michael <sup>1</sup> , Nicholas Liotta <sup>1</sup> , Kejun Guo <sup>2,3,4</sup> , Kaylee
5	L. Mickens <sup>2,3,4</sup> , Brad S. Barrett <sup>2,3,4</sup> , Matthew L. Bendall <sup>1</sup> , Stephanie M. Dillon <sup>2,3,4</sup> , Cara C.
6	Wilson <sup>2,3,4</sup> , Mario L. Santiago <sup>2,3,4</sup> and Douglas F. Nixon <sup>1</sup>
7	
8	Keywords: human endogenous retrovirus (HERV), interferons, human immunodeficiency virus
9	type I (HIV-I), Endogenous Retroelement (ERE), Long interspersed nuclear element (LINE)
10	
11	<sup>1</sup> Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York,
12	NY, United States of America.
13	<sup>2</sup> Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United
14	States of America.
15	<sup>3</sup> RNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, United
16	States of America.
17	<sup>4</sup> Department of Immunology and Microbiology, University of Colorado School of Medicine,
18	Aurora, CO, United States of America.
19	
20	Correspondence:
21	Nicholas Dopkins, PhD
22	Email: <u>nid4009@med.cornell.edu</u>
23	

# 24 Summary

26	Background: Endogenous retroelements (EREs), including human endogenous retroviruses
27	(HERVs) and long interspersed nuclear elements (LINEs), comprise almost half of the human
28	genome. HIV-1 infects a target cell already possessing ancient retroviral genetic material, and
29	exogenous HIV-1 infection modulates the expression of cell associated EREs. Following initial
30	HIV-1 infection, there is a rapid destruction of CD4+ cells in the gut associated lymphoid tissue
31	(GALT). Our previous studies of the interferome in the gut suggest potential mechanisms
32	regarding how IFNb may drive HIV-1 gut pathogenesis. As ERE activity is suggested to partake
33	in type 1 immune responses and is incredibly sensitive to viral infections, we sought to elucidate
34	underlying interactions between ERE expression and GALT dynamics in PLWH.
35	
36	Methods: ERE expression profiles from bulk RNA sequencing of colon biopsies and PBMC
37	were compared between a cohort of PLWH prior to or within 7 days of initiating antiretroviral
38	therapy (ART) (n=19) and uninfected controls (n=13). Individual EREs were then compared
39	with the profiling of uninfected gut CD4+ T cells activated with type 1 interferons (IFN-Is) (n=3)
40	to elucidate potential mechanisms for their induction in PLWH.
41	
42	Findings: 59 EREs were differentially expressed in the colon of PLWH when compared to
43	uninfected controls (Wald's Test with Benjamin-Hochberg correction: padj < 0.05 and FC $\leq$ -1
44	or $\geq$ 1). Of these 59, 12 EREs were downregulated in PLWH and 47 were upregulated. Colonic
45	expression of the ERE loci LTR19_12p13.31 and L1FLnI_1q23.1s showed significant
46	correlations with CD8+ T Cells and dendritic cell subset frequencies in the GI tract (Spearman's

47	$Correlation: \ p \ value < 0.05). \ Furthermore \ L1FLnI\_1q23.1s \ showed \ a \ significant \ upregulation \ in$
48	the blood of PLWH when compared to uninfected controls (T test: $p < 0.05$ ) suggesting a
49	common mechanism of differential ERE expression in PBMC and GALT.
50	
51	Interpretation: ERE activity has been largely understudied in genomic characterizations of
52	human pathologies. We show that the activity of certain EREs in the GI tract of PLWH is
53	deregulated, supporting our hypotheses that their underlying activity could function as
54	(bio)markers and potential mediators of pathogenesis in HIV-1 reservoirs.
55	
56	Funding: NCI CA260691 (DFN) and NIAID UM1AI164559 (DFN).
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

## 70 Introduction

71 Human immunodeficiency virus type I (HIV-1) is a retrovirus that infects immune cells by binding to receptors on the cell surface<sup>1</sup>. HIV-1 infects host cells by integrating a copy of the 72 73 viral genome into the host genome, resulting in proviruses that then hijack the host cell's replicative machinery to produce the building blocks of infectious particles<sup>1</sup>. The HIV-1 lifecycle 74 75 may rapidly deplete host CD4+ T cell populations and disrupt global immune dynamics<sup>2</sup>. 76 Disruptions to the host immune system predispose people living with HIV-1 (PLWH) to lifethreatening comorbidities<sup>3</sup>. Since 1996, life expectancy and quality of life for PLWH have risen 77 78 due to the advent of antiretroviral therapies (ARTs) that pharmacologically inhibit key processes of the retroviral life cycle<sup>4</sup>. Unfortunately, ART merely suppresses retroviral processes, 79 80 emphasizing the need for cure strategies that rid individuals of latent proviral reservoirs which may resume infectious particle formation after a lapse in treamtent<sup>5,6</sup>. One such reservoir site is 81 the gastrointestinal (GI) associated lymphoid tissue (GALT)<sup>7,8</sup>, which is particularly rich in 82 CD4+ T cells<sup>9</sup>. HIV-1 induced immunopathologies in the GALT are associated with severe 83 comorbidities in PLWH<sup>10,11</sup>. Many of these pathologies could be sustained by the accumulation 84 of plasmacytoid dendritic cells (pDCs) that are trafficked to the GI tract during chronic HIV-1 85 86 infection<sup>12</sup>. Models of Simian Immunodeficiency Virus (SIV), a retrovirus closely related to 87 HIV-1, demonstrate that pDCs traffic from the circulation, where they are depleted, to the GALT, 88 where their overabundance contributes to immunopathologies that allow the site to become the primary source of viral replication<sup>13,14</sup>. pDCs reflect a unique subset of DCs whose primary 89 90 function is not antigen presentation but is instead immunomodulation through the release of cytokines<sup>15</sup>. In the acute stages of HIV-1 infection, pDCs produce type 1 interferons (IFN-Is) as 91 one of the first lines of defense against the virus<sup>16</sup>, and are therefore protective. However, the 92

93	sustainment of their IFN-I production during the chronic stages of infection exhausts and
94	deregulates antiviral immunity, negatively impacting the health of PLWH <sup>12,16–18</sup> .
95	To better characterize how immunopathologies in PLWH develop, we investigated how
96	endogenous retroelement (ERE) expression may underlie the development of HIV-1 induced
97	immune deregulation. EREs are highly abundant sequences estimated to make up roughly ~40%
98	of the human genome <sup>19</sup> . In humans, EREs include long interspersed nuclear elements (LINEs),
99	short interspersed nuclear elements (SINEs), and human endogenous retroviruses (HERVs) <sup>20</sup> .
100	Previous studies have demonstrated that ERE activity is highly susceptible to change during
101	infection with HIV-1 <sup>21–31</sup> . While IFN-I signaling may activate EREs proximal to interferon
102	stimulated genes (ISGs), other EREs, such as HERV elements, can be directly trans-activated by
103	HIV-1 cofactors due to high sequence homology between endogenous and exogenous
104	retroviruses <sup>21,22,24,32,33</sup> . This homology can be so substantial that certain HERV-K18 and HERV-
105	W products can be incorporated in the assembly of HIV-1 particles <sup>34–38</sup> . ERE activity also
106	functions as a major regulator of transcriptional networks that have been co-opted in organismal
107	physiology <sup>39,40</sup> . In immunity, examples of ERE activity cooption suggest their intimate
108	association with the host mounted responses <sup>41,42</sup> . Recurrent observations continually reinforce
109	hypotheses that EREs likely participate in human health and disease through poorly understood
110	mechanisms <sup>42-46</sup> . The activity of multiple HERVs <sup>21-28</sup> and LINEs <sup>29,30</sup> is altered during HIV-1
111	infection, which then impacts host gene expression <sup>24</sup> , packaging of HIV-1 particles <sup>34–38</sup> , and
112	immunity <sup>25,47</sup> . For the purpose of further defining HIV-1 mediated gut pathogenesis, we sought
113	to characterize how ERE activity at the RNA level is modulated in the gut microenvironment of
114	PLWH. Since EREs have been largely overlooked in genomic approaches to classify underlying

components of human pathologies, we hypothesize that their consideration would identify novelmarkers of HIV-1 pathogenesis in the gut.

117	ERE expression at the RNA level was quantified in colon biopsies collected from a
118	cohort of viremic individuals prior to or at the initiation of ART <sup>17</sup> to identify those best
119	correlating with viral load. We next overlaid these findings with IFN-I stimulated gut CD4+ T
120	cells to estimate if the differential expression of EREs in the gut of PLWH is driven by the HIV-1
121	lifecycle or by innate immunopathologies. Collectively, our analyses demonstrate that a subset of
122	ERE loci are impacted in PLWH. The bulk of PLWH-upregulated EREs in the gut are not
123	upregulated by IFN-I stimulation of gut CD4+ T cells, suggesting their activation by other
124	aspects of the HIV-1 life cycle or the host response. Two identified EREs, LTR19_12p13.31 and
125	L1FLnI_1q23.1s, further correlated with myeloid and lymphoid immune cell abundances.
126	Collectively, incorporation of the GI-specific expression of LTR19_12p13.31 and
127	L1FLnI_1q23.1s can better define HIV-1 driven immunopathologies of the GALT, and the
128	expression of these elements may possess underlying roles in pathogenesis.
129	
130	Methods
131	Locus-specific quantification of ERE expression at the RNA level
132	RNA sequencing FASTQ files of colon pinch biopsies and interferome arrays of
133	uninfected CD4+ T cells were obtained from a previously published study <sup>17</sup> under the Bioproject
134	accession numbers "PRJNA558500" and "PRJNA558974", respectively. RNA sequencing
135	FASTQ files performed on the PBMC fraction from the same participants are available under the
136	Bioproject accession number "PRJNA659373". FASTQ files were aligned to the human genome
137	build 38 (hg38) using STAR (v2.7.9.a) <sup>48</sup> . STAR alignment was performed using the parameters

- 138 "--outSAMstrandField intronMotif --outFilterMultimapNmax 200 --winAnchorMultimapNmax
- 139 200" for the purpose of capturing multimapping ERE reads. We then used Telescope  $(v1.0.3)^{49}$ ,
- 140 which utilizes an expectation-maximization algorithm to improve upon the definition of
- 141 ubiquitously mapping ERE transcripts to a custom annotation, for locus-specific approximation
- 142 of ERE expression. The Telescope assign module was performed using the parameters "--
- 143 theta\_prior 200000 -- max\_iter 1000" to align reads to a custom annotation of EREs accessible at
- 144 <u>https://github.com/mlbendall/telescope\_annotation\_db</u>. Metadata for the ERE annotation
- 145 predicting the intronic, exonic, and intergenic status of individual loci in the Telescope
- 146 annotation relative to coding gene annotations can be found at
- 147 <u>https://github.com/liniguez/Telescope\_MetaAnnotations</u>. Original code produced for analysis
- 148 can be accessed at <u>https://github.com/NicholasDopkins/JuneHIVMucosa</u>.
- 149
- 150 Differential expression analysis

151 Lowly abundant EREs were filtered from downstream analysis by ensuring that all EREs 152 possessed at least 2 reads within 10% of the total samples. Differential expression analysis was 153 performed between the ERE expression profiles of uninfected control and PLWH colon biopsies using standard DESEQ2 (v1.30.1)<sup>50</sup> parameters. Differential expression analysis was performed 154 155 between the ERE expression profiles of IFN-I stimulated gut CD4+ T cells using DESEQ2 with the parameters "parallel = T" and "betaPrior = T". Results were extracted as DESEQ objects, 156 157 with a numbered contrast of each group compared against all others. Differentially expressed EREs were visualized with the packages pheatmap (v1.0.12), ggVennDiagram (v1.2.2)<sup>51</sup> and 158 159 EnhancedVolcano (v1.8.0). Individual EREs were visualized with a custom function that overlays geom jitter and geom boxplot functions provided by ggplot2  $v(3.3.5)^{52}$  to produce a 160

161	Tukey box and whisker plot that displays individual replicates. Clinical parameters of
162	immunopathologies were provided by previously published metadata <sup>17,18,53,54</sup> and a table
163	summary is available at
164	https://github.com/NicholasDopkins/JuneHIVMucosa/blob/main/Metadata.csv. Principal
165	coordinate analyses (PCA) were performed on variance stabilizing transformed DESEQ outputs
166	in order to visualize if untested confounding factors explained observations pertaining to
167	differential expression analyses. PCA generation was performed using PCAtools (v2.2.0) with
168	the variable parameter set to "remove $Var = 0.1$ ".
169	
170	Integrative Genomics Viewer
171	National Center for Biotechnology Information (NCBI) Reference Sequence Database
172	(Refseq) <sup>55</sup> , ENCyclopedia Of DNA Elements <sup>56</sup> (Gencode), and Telescope <sup>49</sup> annotations of the
173	human genome were loaded into Integrative Genomics Viewer <sup>57</sup> (IGV) for alignment of
174	StringTie <sup>58</sup> reconstructed transcriptomes from uninfected controls and PLWH samples.
175	
176	Statistics
177	Standard DESEQ2 statistics of Wald's Test with Benjamin-Hochberg correction of p
178	values were utilized for the identification of significantly deregulated EREs between uninfected
179	controls and PLWH samples. EREs a log2 fold change of >1 or <-1 and an adjusted p value
180	(padj) of <0.05 were deemed significantly differentially expressed. Statistical values for
181	correlations between clinical parameters and ERE expression were conducted using Pearson's
182	correlation coefficient values provided by ggplot2. To elucidate values of significance regarding
183	of ERE expression between experimental groups, T tests were used to gather significance values

184 when stated. For significance of post hoc tests the following scale is used to indicate p values

185 when applicable: ns, p > 0.05; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.005

186

187 Clinical cohort

188 ERE expression analyses were conducted using FASTQ files from previously generated RNAseq 189 data collected from colonic tissue and PBMC fractions collected from 19 PLWH and 13 age- and 190 sex-matched controls, and associations with features of HIV-1 pathogenesis were determined using archived datasets of colon and systemic immunological and virological parameters<sup>17,18,53,54</sup>. 191 192 On average, PLWH had been infected with HIV-1 (defined by the first HIV-1 seropositive test) 193 for  $5.25\pm1.1$  (mean  $\pm$  SEM) years. PLWH were ART-naive or were not on ART for more than 7 194 days in the preceding 6 months, and had CD4 T cell counts >200 cells/µl within 3 months of clinical visit. Exclusion criteria for both cohorts are extensively detailed elsewhere<sup>53</sup>. In addition 195 196 to blood samples, study participants underwent a flexible sigmoidoscopy with multiple colon 197 pinch biopsies obtained. Clinical characteristics for the study participants included in this current 198 study are detailed in Supplemental Table 1.

199

200 Immune system characterization of PLWH and uninfected controls

201 Methods used to generate the archived datasets have been extensively detailed<sup>17,18,53,54,59,60</sup>. In 202 brief, indicators of systemic inflammation were assessed with plasma IL-6 concentrations by 203 ELISA, and microbial translocation was measured by plasma LPS concentrations with the 204 Limulus Amebocyte Lysate assay<sup>53</sup>. Frequencies of colon mDCs, pDCs, and T cells were 205 determined using multi-color flow cytometry<sup>53,54</sup> and expressed as an absolute number per gram 206 of tissue based on the frequency within viable CD45+ cells, initial cell counts, and biopsy

207	weights. Colon tissue HIV-1 RNA was quantified by real-time PCR and HIV-1 RNA copy
208	numbers normalized per CD4 T cell within each biopsy calculated by the percent of all viable
209	cells that were CD45+CD3+CD4+ as determined by flow cytometry and weight of each biopsy
210	and reported as HIV-1 RNA per million CD4 T cell <sup>53</sup> .
211	
212	Ethics Statement
213	Analyses performed in this study were performed on deidentified and publicly available or
214	previously archived data. The original clinical study was approved by the Colorado Multiple
215	Institutional Review Board and all study participants voluntarily gave written, informed
216	consent <sup>17,18,53,54</sup> .
217	
218	Role of Funders
219	The funding bodies had no influence on the planning, conduction and analysis of data
220	performed during this study.
221	
222	Results
223	HIV-1 status influences endogenous retroelement expression in the gut microenvironment
224	Following preprocessing to remove lowly abundant transcripts, we quantified the
225	expression of 13,706 EREs in colon pinch biopsies collected from PLWH in comparison to age
226	and sex-matched HIV-1-uninfected controls (Fig. 1a). Significance in differential expression
227	between controls and PLWH was found for 59 ERE loci (Fig. 1b and Fig. 1c). Of these 59 loci,
228	47 were upregulated and 12 were downregulated in PLWH. All HERVs differentially expressed
229	were upregulated in PLWH when compared to controls. Overall, ERE activity at the RNA level

230	displays discrete changes in the gut microenvironment in viremic individuals prior to the
231	initiation of ART. Further consideration of the phylogenies and chromosomal origin of ERE
232	expression profiles demonstrated no distinctive alterations in PLWH when compared to controls,
233	suggesting no large-scale changes in ERE expression in the gut microenvironment of PLWH
234	(Fig. S1). To infer mechanisms by which HIV-1 infection induces the differential expression of
235	EREs in the gut, we next quantified changes in expression resulting from IFN-I stimulation of
236	uninfected gut-derived CD4+ T cells. IFN-Is do not shift the global landscape of ERE activity at
237	the RNA level (Fig. S2). Discrete changes in locus-specific expression demonstrate that IFN-I
238	activation of uninfected gut CD4+ T cells share upregulated expression of 23 EREs, suggesting
239	that they are IFN-inducible (Fig. S3 and Fig. S4). 7 of these 23 EREs were upregulated in the gut
240	of PLWH, suggesting immune-dependent mechanisms for their in HIV-1 infection, while 35 of
241	the 42 upregulated EREs in PLWH showed no significant induction by IFN-I stimulation (Fig.
242	S5). Collectively, HIV-1 infection upregulates specific EREs in the gut of PLWH through both
243	IFN-dependent and IFN-independent mechanisms.

244

245 Correlation between gut endogenous retroelement expression and viral load in people living
246 with HIV-1

Pearson's correlation coefficients were calculated for all differentially expressed EREs in
the gut of PLWH to identify any potential links with their expression and HIV-1 infection
severity as determined by circulating HIV-1 viral load. Of the 59 differentially expressed EREs,
three showed near significant (p<0.10) positive correlations between colonic expression and viral</li>
load in PLWH. L1FLnI\_1q23.1s possessed a positive association with viral load in the
circulation (Fig. 2a) and is upregulated in the colon of PLWH when compared to uninfected

253 controls (Fig. 2b). In PBMCs collected from the same participants, expression of

254	L1FLnI_1q23.1s is significantly upregulated in concurrence with gut expression of the element
255	(Fig. 2c). Analysis of IFN-I activated gut CD4+ T cells suggests that IFN alpha 1 (IFNa1) and
256	IFN beta (IFNb) may contribute to the upregulated expression of L1FLnI_1q23.1s, however no
257	IFN-Is yielded significant effects (Fig. 2d). IGV demonstrates that the L1FLnI_1q23.1s locus is
258	an ERE within the Pyrin And HIN Domain Family Member 1 (PYHIN1) gene with minor
259	differences in the putative alignments provided by StringTie for uninfected controls and PLWH
260	samples (Fig. 2e). L1FLnI_5q32o possessed a positive association with viral load in the
261	circulation (Fig. 2f) and is upregulated in the colon of PLWH when compared to controls (Fig.
262	2g). In PBMCs collected from the same study participants, expression of L1FLnI_5q32o is
263	significantly upregulated in concurrence with gut expression of the element (Fig. 2h). Analysis
264	of IFN-I activated gut CD4+ T cells suggests that IFN-Is yield no significant effects on the
265	expression of L1FLnI_5q320 (Fig. 2i). IGV demonstrates that the L1FLnI_5q320 locus is an
266	ERE within the Janus Kinase And Microtubule Interacting Protein 2 (JAKMIP2) gene with no
267	differences in the putative alignments provided by StringTie for PLWH and control samples
268	(Fig. 2j). LTR19_12p13.31 possessed a positive association with viral load in the circulation
269	(Fig. 2k) and is upregulated in the colon of PLWH when compared to controls (Fig. 2l). In
270	PBMCs collected from the same study participants, expression of LTR19_12p13.31 shows a
271	non-significant upregulation (Fig. 2m). Analysis of IFN-I activated gut CD4+ T cells suggests
272	that IFN-Is yield no significant effects on the expression of LTR19_12p13.31 (Fig. 2n). IGV
273	demonstrates that LTR19_12p13.31 locus is an ERE that overlaps the Pregnancy Zone Protein
274	(PZP) and Killer Cell Lectin Like Receptor G1 (KLRG1) genes with a unique transcript in the
275	putative alignments of PLWH samples provided by StringTie (Fig. 2o). Collectively, expression

276	of the EREs L1FLnI_1q23.1s, L1FLnI_5q32o, and LTR19_12p13.31 show associations with
277	blood HIV-1 RNA levels,, and their induction in the gut may likely be independent of IFN-I
278	mediated pathologies.
279	
280	Correlation Between LTR19_12p13.31 and L1FLnI_1q23.1s expression and immune signatures
281	of the gut microenvironment in people living with HIV-1
282	We next analyzed how expression of L1FLnI_1q23.1s, L1FLnI_5q32o and
283	LTR19_12p13.31 correlate with cellular abundances that may be associated with pathogenesis in
284	the gut of PLWH. There were no significant associations between the number colon CD4+ T
285	cells (measured per gram of gut tissue) with LTR19_12p13.31 (Fig. 3a) and L1FLnI_1q23.1s
286	expression (Fig. 3b). LTR19_12p13.31 demonstrated significant positive correlations with the
287	number of colon CD8+ T cells (Fig. 3c) and IFN gamma (IFNy)+CD8+ T cells (Fig. 3e),
288	whereas L1FLnI_1q23.1s demonstrated near significant positive correlations with CD8+ (Fig.
289	3d) and IFNy+CD8+ T cell (Fig. 3f) abundances. Further consideration into dendritic cell (DC)
290	abundances demonstrate that LTR19_12p13.31 (Fig. 3g) and L1FLnI_1q23.1s (Fig. 3h) show
291	near significant positive correlations with CD11c+ myeloid DCs (mDCs), while
292	LTR19_12p13.31 (Fig. 3i) displayed a significant positive correlation and L1FLnI_1q23.1s (Fig.
293	3j) displayed a near significant positive association with plasmacytoid DCs (pDCs). Amongst
294	mDCs, LTR19_12p13.31 (Fig. 3k) and L1FLnI_1q23.1s (Fig. 3l) show significant positive
295	correlations with the CD1c- mDCs, but not with CD1c+ mDCs (Fig. S6), suggesting potential
296	perturbations related to specific mDC subsets <sup>54</sup> . Expression of the ERE L1FLnI_5q320 did not
297	demonstrate positive or negative correlations with CD4+ T cells, CD8+ T cells, IFNy+CD8+ T
298	cells, CD11c+ mDCs, pDCs, or CD1c- mDCs in PLWH (Fig. S7). In analyses of frequencies of

299	CD4 T helper (Th) cell subsets, L1FLnI_1q23.1s significantly positively correlated with
300	IL22+IFNy-IL17- CD4+ T cells (i.e. Th22) and IFNy-IL17+ CD4+ T cells (i.e Th17), and
301	trended towards a significant positive association with IFNy+IL17+ CD4+ T cells (i.e.
302	inflammatory Th17 cells) (Fig. S8). L1FLnI_5q320 (Fig. S9) and LTR19_12p13.31 (Fig. S10)
303	demonstrated no significant correlations with analyzed CD4+ T cell subset abundances in the
304	gut. Furthermore, systemic markers of microbial translocation and inflammation including as
305	plasma lipopolysaccharide (LPS) and interleukin (IL)-6, were analyzed and demonstrated
306	insignificant associations with LTR19_12p13.31, L1FLnI_1q23.1s, or L1FLnI_5q320 expression
307	(Fig. S11). Collectively, LTR19_12p13.31 and L1FLnI_1q23.1s, but not L1FLnI_5q32o, show
308	significant associations with the various innate and adaptive immune cell frequencies in the gut
309	of PLWH.

310

#### 311 Discussion

312 In this study, we leverage modulations in ERE activity at the RNA level in the GI tract of 313 untreated PLWH with frequencies of immune cell populations that are likely critical players in driving HIV-1 gut pathogenesis<sup>11</sup>. As the derepression of EREs may possess immunomodulatory 314 roles in human diseases<sup>42,61</sup>, our results suggest further investigation into their activity in HIV-1 315 316 pathogenesis. By analysis of RNA sequencing from colon biopsies of uninfected controls vs 317 untreated PLWH, we identified 59 differentially expressed EREs associated with HIV. By 318 finding correlations between their colonic expression and circulating viral load, we were able to 319 narrow further investigations to focus on 3 EREs upregulated in PLWH that might indicate the 320 severity of HIV-1 pathogenesis in the gut, or function as markers of immune deregulation. The 321 EREs LTR19 12p13.31 and L1FLnI 1q23.1s best correlated with cellular abundances including

322 higher frequencies of pDCs, CTLs, and CD1c- mDCs. L1FLnI\_5q320 demonstrated no 323 associations with these cellular markers, however, did show associations with differential 324 abundances of CD4+ T cell Th subsets that were not found with LTR19 12p13.31 and 325 L1FLnI 1q23.1s expression. By considering their expression in PBMCs from the same study 326 participants, we observed a significant upregulation in L1FLnI\_1q23.1s expression and a nonsignificant upregulation in LTR19 12p13.31. In accordance with previous studies<sup>22</sup>, we observe 327 328 significant alterations in ERE activity at the RNA level in the PBMC fraction of PLWH and 329 uninfected controls (Fig. S12). This suggests future use of L1FLnI 1q23.1s as a potential 330 circulating biomarker for deregulations of immunity in the gut microenvironment of PLWH, 331 while LTR19\_12p13.31 is more likely an intrinsic marker specific to the GI tract. Collectively, 332 we find significant associations between LTR19\_12p13.31 and L1FLnI\_1q23.1s and cellular 333 dynamics of the GALT in PLWH, further emphasizing their identity as biomarkers or potential 334 mediators of immune deregulation. 335 Previous studies have demonstrated that ERE activity is widely changed in response to the HIV-1 lifecycle<sup>21,22,27,29,31</sup> and certain HIV-1 associated comorbidities<sup>62,63</sup>. ERE expression is 336 337 also susceptible to changes the in epigenetics and immunity that are elicited during viral infections and the host response<sup>64</sup>. While it remains unknown if the changes in expression for 338 339 most EREs result from a bystander effect or by a cooption of host immunity in HIV-1 infection, 340 their activity can be incorporated to better characterize poorly understood immunopathologies in 341 viral infections. Here, we demonstrate that significant correlations can be established between 342 differentially expressed EREs and cellular markers that likely contribute to GI 343 immunopathologies of untreated HIV-1 infection. Some limitations of this study concern bulk

344 RNA sequencing approaches utilized, leaving the data unable to discern what cell types are

345 responsible for the overexpression of differentially expressed EREs. As the cellular composition 346 of the sequenced tissues fluctuates with disease severity, it is unclear whether the phenotype or 347 mere abundance of disproportionate cell types, such as pDCs and CTLs, is responsible for their 348 expression. Future studies that accurately quantify ERE expression from single cell RNA 349 sequencing data that were not available from this cohort would provide further insight into the 350 activation state of these EREs in the GI tract of PLWH. Additionally, due to the poorly defined 351 molecular characteristics and low copy number of LTR19 HERV sequences, exceedingly little is 352 known about their potential roles in health and disease. LTR19 sequences are a member of the 353 HERVFA clade and are estimated to only possess roughly  $\sim 15$  copies in the human genome<sup>65</sup>. 354 In conclusion, this study provides the first correlative link between ERE expression and 355 the deregulations of GALT observed in untreated HIV-1 infection. While EREs can be 356 modulated in context dependent manners by various aspects of HIV-1 infection, their potential 357 roles in systemic immunity in the GI tract have remained undetermined. We also demonstrate 358 that the IFN-I response mediates ERE expression in uninfected gut CD4+ T cells, however this 359 only appears to be responsible for a distinct subset of roughly 7 differentially expressed 360 elements. It is thus unclear if the HIV-1 lifecycle or IFN-I activity on CD4- cell types in the 361 GALT are responsible for changes in ERE activity. We find that LTR19\_12p13.31 and 362 L1FLnI\_1q23.1s are promising markers of HIV-1 pathogenesis in the gut and may possess 363 undetermined roles in determining cellular composition. This study also provides one of the first 364 observations of a differentially expressed LTR19 elements in a human disease, thus emphasizing 365 the importance of their further study.

366

#### 367 **Contributors**

368 ND co-designed the study, co-prepared the first manuscript draft, co-performed data analyses, 369 co-curated code, led statistical analyses, and curated figures. TF co-prepared the first manuscript 370 draft, co-performed data analyses, co-performed statistical analysis, co-curated code, and 371 provided intellectual input critical to analysis. SM co-designed the study, co-prepared the first 372 manuscript draft, co-performed data analyses, and provided intellectual input critical to data 373 interpretation. NL co-performed analyses and co-curated code. KG provided intellectual input 374 critical to hypothesis generation and co-provided data access. KLM provided intellectual input 375 critical to hypothesis generation and co-provided data access. BSB provided intellectual input 376 critical to hypothesis generation and co-provided data access. MLB provided intellectual input 377 critical to hypothesis testing. SMD provided intellectual input critical to hypothesis generation 378 and testing, co-provided data access, and performed immunological analysis of the gut 379 microenvironment. CCW provided intellectual input critical to hypothesis generation and co-380 provided data access. DFN co-designed the study and co-prepared the first manuscript draft. 381 MLS co-designed the study, co-prepared the first manuscript draft, and co-provided data access. 382 All authors contributed to data interpretation, discussion regarding significances, and editing of 383 the manuscript. All authors have read and approved the final manuscript. 384

- 385 **Declaration of Interests**
- 386 All authors have no potential conflicts of interests to disclose.

387

388 Acknowledgments

389 These works are supported by US NIH grants NCI CA260691 (DFN) and NIAID
390 UM1AI164559 (DFN).

## 391

# 392 Data Sharing Statement

393	FASTQ from the bulk RNA sequencing reanalyzed by this study can be accessed at the
394	NCBI sequence read archive (SRA) under PRJNA558974 and PRJNA558500. Code for analysis
395	can be accessed at https://github.com/NicholasDopkins/JuneHIVMucosa. Details on running the
396	Telescope pipeline can be accessed at <u>https://github.com/mlbendall/telescope</u> .
397	
398	
399	
400	
401	
402	
403	
404	
405	
406	
407	
408	
409	
410	
411	
412	
413	

## 414 **References**

- 415 1. Justiz Vaillant, A. A. & Gulick, P. G. HIV Disease Current Practice. in *StatPearls* (StatPearls
- 416 Publishing, 2023).
- 417 2. Boasso, A., Shearer, G. M. & Chougnet, C. Immune dysregulation in human
- 418 immunodeficiency virus infection: know it, fix it, prevent it? J. Intern. Med. 265, 78–96
- 419 (2009).
- 420 3. Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. *Nat. Rev. Dis.*
- 421 *Primer* **1**, 1–22 (2015).
- 422 4. Life expectancy of individuals on combination antiretroviral therapy in high-income
- 423 countries: a collaborative analysis of 14 cohort studies. *Lancet* **372**, 293–299 (2008).
- 424 5. Sengupta, S. & Siliciano, R. F. Targeting the latent reservoir for HIV-1. *Immunity* 48, 872–895
  425 (2018).
- 426 6. Veenhuis, R. T. *et al.* Monocyte-derived macrophages contain persistent latent HIV reservoirs.
  427 *Nat. Microbiol.* 8, 833–844 (2023).
- 428 7. Thompson, C. G., Gay, C. L. & Kashuba, A. D. M. HIV Persistence in Gut-Associated
- 429 Lymphoid Tissues: Pharmacological Challenges and Opportunities. *AIDS Res. Hum.*
- 430 *Retroviruses* **33**, 513–523 (2017).
- 431 8. Kelley, C. F. et al. HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1
- 432 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the
- 433 Rectum. J. Infect. Dis. 204, 761–767 (2011).
- 434 9. Mowat, A. McI. & Viney, J. L. The anatomical basis of intestinal immunity. *Immunol. Rev.*
- 435 **156**, 145–166 (1997).

<ul> <li>Guadalupe, M. <i>et al.</i> Severe CD4 <sup>+</sup> T-Cell Depletion in Gut Lymphoid Tissue during</li> <li>Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in</li> <li>Restoration following Highly Active Antiretroviral Therapy. <i>J. Virol.</i> 77, 11708–11717 (2003)</li> <li>Dillon, S. M. &amp; Wilson, C. C. Gut Innate Immunity and HIV Pathogenesis. <i>Curr.</i></li> <li><i>HIV/AIDS Rep.</i> 18, 128–138 (2021).</li> <li>Lehmann, C. <i>et al.</i> Longitudinal Analysis of Distribution and Function of Plasmacytoid</li> <li>Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>209, 940–949 (2014).</li> </ul>
<ul> <li>Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in</li> <li>Restoration following Highly Active Antiretroviral Therapy. J. Virol. 77, 11708–11717 (2003)</li> <li>11. Dillon, S. M. &amp; Wilson, C. C. Gut Innate Immunity and HIV Pathogenesis. <i>Curr.</i></li> <li><i>HIV/AIDS Rep.</i> 18, 128–138 (2021).</li> <li>12. Lehmann, C. <i>et al.</i> Longitudinal Analysis of Distribution and Function of Plasmacytoid</li> <li>Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>209, 940–949 (2014).</li> </ul>
<ul> <li>Restoration following Highly Active Antiretroviral Therapy. J. Virol. 77, 11708–11717 (2003)</li> <li>11. Dillon, S. M. &amp; Wilson, C. C. Gut Innate Immunity and HIV Pathogenesis. <i>Curr.</i></li> <li><i>HIV/AIDS Rep.</i> 18, 128–138 (2021).</li> <li>12. Lehmann, C. <i>et al.</i> Longitudinal Analysis of Distribution and Function of Plasmacytoid</li> <li>Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>209, 940–949 (2014).</li> </ul>
<ul> <li>11. Dillon, S. M. &amp; Wilson, C. C. Gut Innate Immunity and HIV Pathogenesis. <i>Curr.</i></li> <li><i>HIV/AIDS Rep.</i> 18, 128–138 (2021).</li> <li>12. Lehmann, C. <i>et al.</i> Longitudinal Analysis of Distribution and Function of Plasmacytoid</li> <li>Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>209, 940–949 (2014).</li> </ul>
<ul> <li><i>HIV/AIDS Rep.</i> 18, 128–138 (2021).</li> <li>12. Lehmann, C. <i>et al.</i> Longitudinal Analysis of Distribution and Function of Plasmacytoid</li> <li>Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>209, 940–949 (2014).</li> </ul>
<ul> <li>Lehmann, C. <i>et al.</i> Longitudinal Analysis of Distribution and Function of Plasmacytoid</li> <li>Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>209, 940–949 (2014).</li> </ul>
<ul> <li>442 Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. <i>J. Infect. Dis.</i></li> <li>443 <b>209</b>, 940–949 (2014).</li> </ul>
443 <b>209</b> , 940–949 (2014).
444 15. Ansari, A. A. <i>et al.</i> Blocking of $\alpha 4\beta$ / Gut-Homing Integrin during Acute Infection Leads
to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency
446 Virus-Infected Rhesus Macaques. J. Immunol. <b>186</b> , 1044–1059 (2011).
447 14. Reeves, R. K. <i>et al.</i> SIV Infection Induces Accumulation of Plasmacytoid Dendritic Cells
448 in the Gut Mucosa. J. Infect. Dis. 206, 1462–1468 (2012).
449 15. Villadangos, J. A. & Young, L. Antigen-Presentation Properties of Plasmacytoid
450 Dendritic Cells. <i>Immunity</i> <b>29</b> , 352–361 (2008).
451 16. O'Brien, M., Manches, O. & Bhardwaj, N. Plasmacytoid Dendritic Cells in HIV
452 Infection. in <i>HIV Interactions with Dendritic Cells</i> (eds. Wu, L. & Schwartz, O.) vol. 762 71–
453 107 (Springer New York, 2012).
454 17. Guo, K. <i>et al.</i> Qualitative Differences Between the IFN $\alpha$ subtypes and IFN $\beta$ Influence
455 Chronic Mucosal HIV-1 Pathogenesis. <i>PLoS Pathog.</i> <b>16</b> , e1008986 (2020).
456 18. DILLON, S. M. <i>et al.</i> A Compartmentalized Type I Interferon Response in the Gut
457 During Chronic HIV-1 Infection is Associated with Immunopathogenesis. <i>AIDS Lond. Engl.</i>
<b>32</b> , 1599–1611 (2018).
ור יור

- 459 19. Lander, E. S. *et al.* Initial sequencing and analysis of the human genome. *Nature* 409,
  460 860–921 (2001).
- 461 20. Bourque, G. *et al.* Ten things you should know about transposable elements. *Genome*462 *Biol.* 19, 199 (2018).
- 463 21. Bhardwaj, N., Maldarelli, F., Mellors, J. & Coffin, J. M. HIV-1 Infection Leads to
- 464 Increased Transcription of Human Endogenous Retrovirus HERV-K (HML-2) Proviruses In
- 465 *Vivo* but Not to Increased Virion Production. J. Virol. 88, 11108–11120 (2014).
- 466 22. Contreras-Galindo, R., López, P., Vélez, R. & Yamamura, Y. HIV-1 infection increases
- 467 the expression of human endogenous retroviruses type K (HERV-K) in vitro. *AIDS Res. Hum.*
- 468 *Retroviruses* **23**, 116–122 (2007).
- 469 23. Vincendeau, M. *et al.* Modulation of human endogenous retrovirus (HERV) transcription
  470 during persistent and de novo HIV-1 infection. *Retrovirology* 12, 27 (2015).
- 471 24. Srinivasachar Badarinarayan, S. et al. HIV-1 infection activates endogenous retroviral
- 472 promoters regulating antiviral gene expression. *Nucleic Acids Res.* **48**, 10890–10908 (2020).
- 473 25. Jones, R. B. et al. HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary
- 474 isolates. J. Clin. Invest. **122**, 4473–4489 (2012).
- 475 26. Contreras-Galindo, R., Almodóvar-Camacho, S., González-Ramírez, S., Lorenzo, E. &
- 476 Yamamura, Y. Short Communication: Comparative Longitudinal Studies of HERV-K and
- 477 HIV-1 RNA Titers in HIV-1-Infected Patients Receiving Successful versus Unsuccessful
- 478 Highly Active Antiretroviral Therapy. *AIDS Res. Hum. Retroviruses* 23, 1083–1086 (2007).
- 479 27. Gonzalez-Hernandez, M. J. et al. Expression of Human Endogenous Retrovirus Type K
- 480 (HML-2) Is Activated by the Tat Protein of HIV-1. J. Virol. 86, 7790–7805 (2012).

- 481 28. Contreras-Galindo, R. et al. HIV infection reveals widespread expansion of novel
- 482 centromeric human endogenous retroviruses. *Genome Res.* 23, 1505–1513 (2013).
- 483 29. Jones, R. B. et al. LINE-1 retrotransposable element DNA accumulates in HIV-1-infected
- 484 cells. J. Virol. 87, 13307–13320 (2013).
- 485 30. Jones, R. B. et al. HIV-1 infection induces retrotransposition of LINE-1 elements.
- 486 *Retrovirology* **6**, P43, 1742-4690-6-S2-P43 (2009).
- 487 31. O'Carroll, I. P. et al. Structural Mimicry Drives HIV-1 Rev-Mediated HERV-K
- 488 Expression. J. Mol. Biol. 432, 166711 (2020).
- 489 32. van der Kuyl, A. C. HIV infection and HERV expression: a review. *Retrovirology* **9**, 6
- 490 (2012).
- 491 33. Kyriakou, E. & Magiorkinis, G. Interplay between endogenous and exogenous human
  492 retroviruses. *Trends Microbiol.* 31, 933–946 (2023).
- 493 34. Brinzevich, D. et al. HIV-1 Interacts with Human Endogenous Retrovirus K (HML-2)
- 494 Envelopes Derived from Human Primary Lymphocytes. J. Virol. 88, 6213–6223 (2014).
- 495 35. An, D. S., Xie, Y. & Chen, I. S. Y. Envelope Gene of the Human Endogenous Retrovirus
- 496 HERV-W Encodes a Functional Retrovirus Envelope. J. Virol. **75**, 3488–3489 (2001).
- 497 36. Ogata, T., Okui, N., Sakuma, R., Kobayashi, N. & Kitamura, Y. Integrase of human
- 498 endogenous retrovirus K-10 supports the replication of replication-incompetent Int- human
- 499 immunodeficiency virus type 1 mutant. Jpn. J. Infect. Dis. 52, 251–252 (1999).
- 500 37. Monde, K., Contreras-Galindo, R., Kaplan, M. H., Markovitz, D. M. & Ono, A. Human
- 501 Endogenous Retrovirus K Gag Coassembles with HIV-1 Gag and Reduces the Release
- 502 Efficiency and Infectivity of HIV-1. J. Virol. **86**, 11194–11208 (2012).

- 503 38. Terry, S. N. *et al.* Expression of HERV-K108 envelope interferes with HIV-1 production.
  504 *Virology* 509, 52–59 (2017).
- 505 39. Fueyo, R., Judd, J., Feschotte, C. & Wysocka, J. Roles of transposable elements in the
- 506 regulation of mammalian transcription. *Nat. Rev. Mol. Cell Biol.* **23**, 481–497 (2022).
- 507 40. Du, A. Y., Chobirko, J. D., Zhuo, X., Feschotte, C. & Wang, T. Regulatory Transposable
- 508 *Elements in the Encyclopedia of DNA Elements.*
- 509 http://biorxiv.org/lookup/doi/10.1101/2023.09.05.556380 (2023)
- 510 doi:10.1101/2023.09.05.556380.
- 511 41. Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory evolution of innate immunity
- through co-option of endogenous retroviruses. *Science* **351**, 1083–1087 (2016).
- 513 42. Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the
  514 bad with the good. *Nat. Rev. Immunol.* 16, 207–219 (2016).
- 515 43. Payer, L. M. & Burns, K. H. Transposable elements in human genetic disease. *Nat. Rev.*516 *Genet.* 20, 760–772 (2019).
- 517 44. Küry, P. *et al.* Human Endogenous Retroviruses in Neurological Diseases. *Trends Mol.*518 *Med.* 24, 379–394 (2018).
- 519 45. Jansz, N. & Faulkner, G. J. Endogenous retroviruses in the origins and treatment of
  520 cancer. *Genome Biol.* 22, 147 (2021).
- 521 46. Dopkins, N. & Nixon, D. F. Activation of human endogenous retroviruses and its
- 522 physiological consequences. *Nat. Rev. Mol. Cell Biol.* (2023) doi:10.1038/s41580-023-00674523 z.
- 524 47. De Mulder, M. et al. Anti-HERV-K (HML-2) capsid antibody responses in HIV elite
- 525 controllers. *Retrovirology* **14**, 41 (2017).

- 526 48. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21
  527 (2013).
- 528 49. Bendall, M. L. *et al.* Telescope: Characterization of the retrotranscriptome by accurate
- 529 estimation of transposable element expression. *PLoS Comput. Biol.* **15**, e1006453 (2019).
- 530 50. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
- for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 532 51. Gao, C.-H., Yu, G. & Cai, P. ggVennDiagram: An Intuitive, Easy-to-Use, and Highly
- 533 Customizable R Package to Generate Venn Diagram. *Front. Genet.* **12**, 706907 (2021).
- 534 52. Ito, K. & Murphy, D. Application of ggplot2 to Pharmacometric Graphics. CPT
- 535 Pharmacomet. Syst. Pharmacol. 2, e79 (2013).
- 536 53. Dillon, S. M. et al. An altered intestinal mucosal microbiome in HIV-1 infection is
- 537 associated with mucosal and systemic immune activation and endotoxemia. *Mucosal*
- 538 *Immunol.* **7**, 983–994 (2014).
- 539 54. Dillon, S. M. *et al.* Gut dendritic cell activation links an altered colonic microbiome to
- 540 mucosal and systemic T-cell activation in untreated HIV-1 infection. *Mucosal Immunol.* 9, 24–
- 541 37 (2016).
- 542 55. O'Leary, N. A. et al. Reference sequence (RefSeq) database at NCBI: current status,
- taxonomic expansion, and functional annotation. *Nucleic Acids Res.* 44, D733–D745 (2016).
- 544 56. Harrow, J. *et al.* GENCODE: the reference human genome annotation for The ENCODE
  545 Project. *Genome Res.* 22, 1760–1774 (2012).
- 546 57. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV):
- 547 high-performance genomics data visualization and exploration. *Brief. Bioinform.* 14, 178–192
  548 (2013).

- 549 58. Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from
- 550 RNA-seq reads. *Nat. Biotechnol.* **33**, 290–295 (2015).
- 551 59. Jones, S. T. et al. Altered Immunoglobulin Repertoire and Decreased IgA Somatic
- 552 Hypermutation in the Gut during Chronic HIV-1 Infection. J. Virol. 96, e0097622 (2022).
- 553 60. Dillon, S. M. et al. Granzyme B+ CD4 T cells accumulate in the colon during chronic
- 554 HIV-1 infection. *Gut Microbes* **14**, 2045852 (2022).
- 555 61. Kassiotis, G. The Immunological Conundrum of Endogenous Retroelements. *Annu. Rev.*556 *Immunol.* 41, annurev-immunol-101721-033341 (2023).
- 557 62. Curty, G. et al. Human Endogenous Retrovirus Expression Is Upregulated in the Breast
- 558 Cancer Microenvironment of HIV Infected Women: A Pilot Study. *Front. Oncol.* 10, 553983
  559 (2020).
- 560 63. Dai, L. et al. Transactivation of human endogenous retrovirus K (HERV-K) by KSHV

promotes Kaposi's sarcoma development. *Oncogene* **37**, 4534–4545 (2018).

- 562 64. Macchietto, M. G., Langlois, R. A. & Shen, S. S. Virus-induced transposable element
- 563 expression up-regulation in human and mouse host cells. *Life Sci. Alliance* 3, e201900536
  564 (2020).
- 565 65. Vargiu, L. *et al.* Classification and characterization of human endogenous retroviruses;
  566 mosaic forms are common. *Retrovirology* 13, 7 (2016).
- 567
- 568
- 569
- 570
- 571

#### 572 Figure Legends

573

#### 574 Figure 1. HIV-1 status influences endogenous retroelement expression in the gut

#### 575 microenvironment

- 576 Heatmap demonstrating the normalized per sample abundances of EREs following the
- 577 preprocessing filtering of reads in uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19)
- 578 individuals. ERE reads were filtered to possess at least 2 reads in 10% of the total samples for
- 579 quality assurance (A). Heatmap demonstrating the normalized per sample abundances of EREs
- 580 differentially expressed with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq -1$  between
- uninfected controls (red) (n = 13) and PLWH (blue) (n = 19) gut biopsies. All statistics were
- 582 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default
- 583 parameters for a Benjamini-Hochberg correction (B). Volcano plot demonstrating the average
- fold change  $\geq 1$  or  $\leq -1$  and an adjusted p value of  $\leq 0.05$  and a LFC between uninfected controls (n
- 585 = 13) and PLWH (n = 19) gut biopsies. All statistics were performed in DESEQ using the Wald's
- 586 Test. Adjusted p values were calculated using default parameters for a Benjamini-Hochberg

587 correction (C).

588

# Figure 2. Correlation between gut endogenous retroelement expression and viral load in people living with HIV-1

591 Scatterplot demonstrating the viral load from serum on the X axis and normalized expression of

- 592 L1FLnI\_1q23.1s in colon biopsies on the Y axis. uninfected controls (red) (n = 13) vs PLWH
- 593 (blue) (n = 19) (A). Normalized expression of L1FLnI\_1q23.1s in colon biopsies from
- uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19). Post hoc significance values

595	determined with unpaired T test (B). Normalized expression of L1FLnI_1q23.1s in PBMCs from
596	uninfected controls (red) ( $n = 13$ ) vs PLWH (blue) ( $n = 19$ ). Post hoc significance values
597	determined with unpaired T test (C). Interferome array of L1FLnI_1q23.1s expression following
598	IFN-a1 (n = 3), -a2 (n = 3), -a5 (n = 3), -a8 (n = 3), -a14 (n = 3), and -b (n = 3) treated gut CD4+
599	T cells when compared to mock (m) treatment (n=3). ANOVA performed for significance with
600	post hoc significance values determined via unpaired T test (D). IGV representation of
601	L1FLnI_1q23.1s locus provided by the Telescope annotation in the Refseq and Gencode
602	annotations. StringTie reconstructed transcriptomes demonstrate putative transcripts present in
603	sequencing collected from the colon of uninfected controls and PLWH individuals (E).
604	Scatterplot demonstrating the viral load from serum on the X axis and normalized expression of
605	L1FLnI_5q320 in colon biopsies on the Y axis. Uninfected controls (red) ( $n = 13$ ) vs PLWH
606	(blue) (n = 19) (F). Normalized expression of L1FLnI_5q320 in colon biopsies from uninfected
607	controls (red) $(n = 13)$ vs PLWH (blue) $(n = 19)$ . Post hoc significance values determined with
608	unpaired T test (G). Normalized expression of L1FLnI_5q320 in PBMCs from uninfected
609	controls (red) ( $n = 13$ ) vs PLWH (blue) ( $n = 19$ ). Post hoc significance values determined with
610	unpaired T test (H). Interferome array of L1FLnI_5q320 expression following IFN-a1 ( $n = 3$ ), -
611	a2 (n = 3), -a5 (n = 3), -a8 (n = 3), -a14 (n = 3), and -b (n = 3) treated gut CD4+ T cells when
612	compared to mock (m) treatment (n=3). ANOVA performed for significance with post hoc
613	significance values determined via unpaired T test (I). IGV representation of L1FLnI_5q320
614	locus provided by the Telescope annotation in the Refseq and Gencode annotations. StringTie
615	reconstructed transcriptomes demonstrate putative transcripts present in sequencing collected
616	from the colon of uninfected controls and PLWH individuals (J). Scatterplot demonstrating the
617	viral load from serum on the X axis and normalized expression of LTR19_12p13.31 in colon

biopsies on the Y axis. uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19) (K).

619 Normalized expression of LTR19\_12p13.31 in colon biopsies from uninfected controls (red) (n =

620 13) vs PLWH (blue) (n = 19). Post hoc significance values determined with unpaired T test (L).

621 Normalized expression of LTR19\_12p13.31 in PBMCs from uninfected controls (red) (n = 13)

622 vs PLWH (blue) (n = 19). Post hoc significance values determined with unpaired T test (M).

623 Interferome array of L1FLnI\_1q23.1s expression following IFN-a1 (n = 3), -a2 (n = 3), -a5 (n =

624 3), -a8 (n = 3), -a14 (n = 3), and -b (n = 3) treated gut CD4+ T cells when compared to mock (m)

625 treatment (n=3). ANOVA performed for significance with post hoc significance values

626 determined via unpaired T test (N). IGV representation of LTR19\_12p13.31 locus provided by

the Telescope annotation in the Refseq and Gencode annotations. StringTie reconstructed

628 transcriptomes demonstrate putative transcripts present in sequencing collected from the colon of

629 uninfected controls and PLWH individuals (O).

630

#### 631 Figure 3. Correlation Between LTR19\_12p13.31 and L1FLnI\_1q23.1s expression and

632 immune signatures of the gut microenvironment in people living with HIV-1.

For all samples uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19). Scatterplot

634 demonstrating the CD4+ T Cells per gram on the X axis and normalized expression of

635 LTR19\_12p13.31 in colon biopsies on the Y axis (A). Scatterplot demonstrating the CD4+ T

636 Cells per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on

the Y axis (B). Scatterplot demonstrating the CD8+ T Cells per gram on the X axis and

normalized expression of LTR19\_12p13.31 in colon biopsies on the Y axis (C). Scatterplot

639 demonstrating the CD8+ T Cells per gram on the X axis and normalized expression of

640 L1FLnI\_1q23.1s in colon biopsies on the Y axis (D). Scatterplot demonstrating the IFNy+CD8+

641	T Cells per gram on the X axis and normalized expression of LTR19_12p13.31 in colon biopsies
642	on the Y axis (E). Scatterplot demonstrating the IFNy+CD8+ T Cells per gram on the X axis and
643	normalized expression of L1FLnI_1q23.1s in colon biopsies on the Y axis (F). Scatterplot
644	demonstrating the CD11c+ mDCs per gram on the X axis and normalized expression of
645	LTR19_12p13.31 in colon biopsies on the Y axis (G). Scatterplot demonstrating the CD11c+
646	mDCs per gram on the X axis and normalized expression of L1FLnI_1q23.1s in colon biopsies
647	on the Y axis (H). Scatterplot demonstrating the pDCs per gram on the X axis and normalized
648	expression of LTR19_12p13.31 in colon biopsies on the Y axis (I). Scatterplot demonstrating the
649	pDCs per gram on the X axis and normalized expression of L1FLnI_1q23.1s in colon biopsies on
650	the Y axis (J). Scatterplot demonstrating the CD1c- mDCs per gram on the X axis and
651	normalized expression of LTR19_12p13.31 in colon biopsies on the Y axis (K). Scatterplot
652	demonstrating the CD1c- mDCs per gram on the X axis and normalized expression of
653	L1FLnI_1q23.1s in colon biopsies on the Y axis (L).
654	
655	
656	
657	
658	
659	
660	
661	
662	
663	

# 664 Supplemental Legends

665

666	Figure S1: Characterization of ERE expression profiles in the colonic microenvironment of
667	PLWH. Principal component analysis (PCA) plot based solely on endogenous retroelement
668	(ERE) abundances demonstrate variance in sample distribution between uninfected controls (red)
669	(n = 13) and PLWH (blue) $(n = 19)$ gut biopsies (A). Stacked bar charts demonstrating mean
670	abundance of exonic, intronic, and intergenic EREs as the average proportion of ERE denoted
671	reads from gut biopsies collected from uninfected controls ( $n = 13$ ) and PLWH ( $n = 19$ )
672	individuals (B). Stacked bar charts demonstrating mean abundance of LINE1 and HERV
673	elements as the average proportion of ERE denoted reads from gut biopsies collected from
674	uninfected controls ( $n = 13$ ) and PLWH ( $n = 19$ ) individuals (C). Stacked bar charts
675	demonstrating the proportional abundance of chromosomes of origin for ERE loci from gut
676	biopsies collected from uninfected controls ( $n = 13$ ) and PLWH ( $n = 19$ ) individuals (D). Stacked
677	bar charts demonstrating category of EREs the average proportion of TE denoted reads from gut
678	biopsies collected from uninfected controls ( $n = 13$ ) and PLWH ( $n = 19$ ) individuals (E). Stacked
679	bar charts demonstrating mean abundance of transposable element (TE) families as the average
680	proportion of ERE denoted reads from gut biopsies collected from uninfected controls ( $n = 13$ )
681	and PLWH $(n = 19)$ individuals (F).

682

#### 683 Figure S2: Characterization of ERE expression profiles in uninfected gut CD4+ T cells

684 activated with IFN-Is. PCA plot based solely on ERE abundances demonstrate variance in

sample distribution between mock (m) (n=3), IFN $\alpha$ 1 (a1) (n = 3), IFN $\alpha$ 2 (a2) (n = 3), IFN $\alpha$ 5 (a5)

686 (n = 3), IFN $\alpha$ 8 (a8) (n = 3), IFN $\alpha$ 14 (a14) (n = 3), and IFN $\beta$  (b) (n = 3) treated gut CD4+ T cells

687 (A). Stacked bar charts demonstrating mean abundance of exonic, intronic, and intergenic TEs as 688 the average proportion of ERE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 689 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells (B). Stacked bar charts demonstrating 690 mean abundance of LINE1 and HERV elements as the average proportion of ERE denoted reads 691 from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut 692 CD4+ T cells (C). Stacked bar charts demonstrating the chromosomal location of ERE denoted 693 reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated 694 gut CD4+ T cells (D). Stacked bar charts demonstrating ERE category as the average proportion 695 of TE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and 696 b (n =3) treated gut CD4+ T cells (E). Stacked bar charts demonstrating mean abundance of TE 697 families as the average proportion of TE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n 698 = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells (F).

699

#### 700 Figure S3: IFN-Is induce the differential expression of EREs in gut CD4+ T cells. Heatmap 701 demonstrating the normalized per sample abundances of TEs following the preprocessing 702 filtering of reads in m (gold) (n=3), a1 (purple) (n = 3), a2 (pink) (n = 3), a5 (green) (n = 3), a8 703 (blue) (n = 3), a14 (red) (n = 3), and b (teal) (n = 3) treated gut CD4+ T Cells. ERE reads were 704 filtered to possess at least 2 reads in 10% of the total samples for quality assurance (A). 705 Heatmap demonstrating the normalized per sample abundances of EREs differentially expressed 706 with an adjusted p value of $\leq 0.05$ and a LFC $\geq 1$ or $\leq -1$ between m (red) (n=3) and a1 (blue) 707 (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ using the Wald's Test. 708 Adjusted p values were calculated using default parameters for a Benjamini-Hochberg correction 709 (B). Heatmap demonstrating the normalized per sample abundances of EREs differentially

710	expressed with an adjusted p value of $\leq 0.05$ and a LFC $\geq 1$ or $\leq -1$ between m (red) (n=3) and a 2
711	(blue) (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ using the Wald's
712	Test. Adjusted p values were calculated using default parameters for a Benjamini-Hochberg
713	correction (C). Heatmap demonstrating the normalized per sample abundances of EREs
714	differentially expressed with an adjusted p value of $\leq 0.05$ and a LFC $\geq 1$ or $\leq -1$ between m (red)
715	(n=3) and a5 (blue) (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ
716	using the Wald's Test. Adjusted p values were calculated using default parameters for a
717	Benjamini-Hochberg correction (D). Heatmap demonstrating the normalized per sample
718	abundances of EREs differentially expressed with an adjusted p value of $\leq 0.05$ and a LFC $\geq 1$
719	or≤-1 between m (red) (n=3) and a8 (blue) (n=3) treated gut CD4+ T cells. All statistics were
720	performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default
721	parameters for a Benjamini-Hochberg correction (E). Heatmap demonstrating the normalized per
722	sample abundances of EREs differentially expressed with an adjusted p value of $\leq 0.05$ and a
723	LFC $\geq$ 1 or $\leq$ -1 between m (red) (n=3) and a14 (blue) (n=3) treated gut CD4+ T cells. All
724	statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated
725	using default parameters for a Benjamini-Hochberg correction (F). Heatmap demonstrating the
726	normalized per sample abundances of EREs differentially expressed with an adjusted p value of
727	$\leq 0.05$ and a LFC $\geq 1$ or $\leq -1$ between m (red) (n=3) and b (blue) (n=3) treated gut CD4+ T cells.
728	All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated
729	using default parameters for a Benjamini-Hochberg correction (G). Venn diagram of shared vs
730	uniquely downregulated ERE loci across a1 ( $n = 3$ ), a2 ( $n = 3$ ), a5 ( $n = 3$ ), a8 ( $n = 3$ ), a14 ( $n = 3$ ),
731	and b (n = 3) treated gut CD4+ T cells when compared to m (H). Venn diagram of shared vs

uniquely upregulated ERE loci across a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3),

and b (n = 3) treated gut CD4+ T cells when compared to m (I).

734

## 735 Figure S4: Upregulation of ERE loci in gut CD4+ T cells activated with IFN-Is. Volcano plot 736 demonstrating the average fold change $\geq 1$ or $\leq -1$ and an adjusted p value of $\leq 0.05$ and a LFC 737 between m (n = 3) and a1 (n = 3) treated gut CD4+ T cells. All statistics were performed in 738 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a 739 Benjamini-Hochberg correction (A). Volcano plot demonstrating the average fold change $\geq 1$ or $\leq -1$ 740 1 and an adjusted p value of $\leq 0.05$ and a LFC between m (n = 3) and a2 (n = 3) treated gut CD4+ 741 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were 742 calculated using default parameters for a Benjamini-Hochberg correction (B). Volcano plot 743 demonstrating the average fold change $\geq 1$ or $\leq -1$ and an adjusted p value of $\leq 0.05$ and a LFC 744 between m (n = 3) and a5 (n = 3) treated gut CD4+ T cells. All statistics were performed in 745 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a 746 Benjamini-Hochberg correction (C). Volcano plot demonstrating the average fold change $\geq 1$ or $\leq$ -747 1 and an adjusted p value of $\leq 0.05$ and a LFC between m (n = 3) and a8 (n = 3) treated gut CD4+ 748 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were 749 calculated using default parameters for a Benjamini-Hochberg correction (D). Volcano plot 750 demonstrating the average fold change $\geq 1$ or $\leq -1$ and an adjusted p value of $\leq 0.05$ and a LFC 751 between m (n = 3) and a14 (n = 3) treated gut CD4+ T cells. All statistics were performed in 752 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a 753 Benjamini-Hochberg correction (E). Volcano plot demonstrating the average fold change $\geq 1$ or $\leq -1$ 754 1 and an adjusted p value of $\leq 0.05$ and a LFC between m (n = 3) and b (n = 3) treated gut CD4+

755 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were

- 756 calculated using default parameters for a Benjamini-Hochberg correction (F).
- 757

#### 758 Figure S5: HIV-1 status and IFN-Is induce 7 shared EREs in the gut microenvironment.

- 759 Venn diagram of shared vs uniquely downregulated TE loci across PLWH (n = 19) vs uninfected
- 760 controls (n = 13) gut biopsies, and a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b
- 761 (n = 3) treated gut CD4+ T cells when compared to m (A). Venn diagram of shared vs uniquely
- vpregulated TE loci across PLWH (n = 19) vs uninfected controls (n = 13) gut biopsies, and a1 (n = 16) vs uninfected controls (n = 16) gut biopsies, and a1 (n = 16) vs uninfected controls (n = 16) gut biopsies, and a1 (n = 16) vs uninfected controls (n = 16) gut biopsies, and a1 (n = 16) vs uninfected controls (n = 16) gut biopsies, and a1 (n = 16) vs uninfected controls (n = 16) vs uni
- 763 = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells when
- compared to m (B). Gut biopsies from uninfected controls (n = 13) and PLWH (n = 19)
- individuals (left) as well interferome assay responses to type 1 interferons (n = 3) (right) show
- significant upregulation in HARLEQUIN\_17q12 (C), HERV4\_4q22.1 (D), MER101\_2p25.2 (E),
- 767 MER4\_7q21.2 (F), L1FLnI\_1p22.2l (G), L1FLnI\_9p21.1ha (H), and L1FLnI\_17q12k (I). All
- statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated
- vising default parameters for a Benjamini-Hochberg correction. Tukey box and whisker plots for
- with the line demonstrating the median of expression while the large dot represents the mean.
- 771

#### 772 Figure S6: EREs of interest in the gut microenvironment show no association with CD1c+

- 773 **mDC abundances**. Gut expression of L1FLnI\_1q23.1s (A), L1FLnI\_5q32o (B), and
- TT4 LTR19\_12p13.31 (C) show no association with CD1c+ mDC abundances in the gut
- 775 microenvironment.
- 776

#### 777 Figure S7: L1FLnI\_5q320 is not associated with major cellular parameters of immune

- deregulation in PLWH. Scatterplot demonstrating the CD4+ T Cells per gram on the X axis and
- normalized expression of L1FLnI\_5q320 in colon biopsies on the Y axis (A). Scatterplot
- 780 demonstrating the CD8+ T Cells per gram on the X axis and normalized expression of
- 781 L1FLnI\_5q320 in colon biopsies on the Y axis (B). Scatterplot demonstrating the IFNy+CD8+ T
- 782 Cells per gram on the X axis and normalized expression of L1FLnI\_5q320 in colon biopsies on
- the Y axis (C). Scatterplot demonstrating the CD11c+ mDCs per gram on the X axis and
- normalized expression of L1FLnI\_5q320 in colon biopsies on the Y axis (D). Scatterplot
- demonstrating the pDCs per gram on the X axis and normalized expression of L1FLnI\_5q320 in
- colon biopsies on the Y axis (E). Scatterplot demonstrating the CD1c- mDCs per gram on the X

axis and normalized expression of L1FLnI\_5q320 in colon biopsies on the Y axis (F).

788

#### 789 Figure S8: Association between colonic L1FLnI\_1q23.1s expression and CD4+ T Cell

results subsets. Scatterplot demonstrating the IFNy-IL17+CD4+ T cells per gram on the X axis and

normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y axis (A). Scatterplot

demonstrating the IFNy+IL17-CD4+ T cells per gram on the X axis and normalized expression

of L1FLnI\_1q23.1s in colon biopsies on the Y axis (B). Scatterplot demonstrating the

794 IFNy+IL17+CD4+ T cells per gram on the X axis and normalized expression of L1FLnI\_1q23.1s

in colon biopsies on the Y axis (C). Scatterplot demonstrating the IL22+IFNy-IL17-CD4+ T cells

per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y

797 axis (D).

799	Figure S9: Association between colonic L1FLnI_5q320 expression and CD4+ T Cell subsets.
800	Scatterplot demonstrating the IFNy-IL17+CD4+ T cells per gram on the X axis and normalized
801	expression of L1FLnI_5q320 in colon biopsies on the Y axis (A). Scatterplot demonstrating the
802	IFNy+IL17-CD4+ T cells per gram on the X axis and normalized expression of L1FLnI_5q32o
803	in colon biopsies on the Y axis (B). Scatterplot demonstrating the IFNy+IL17+CD4+ T cells per
804	gram on the X axis and normalized expression of L1FLnI_5q320 in colon biopsies on the Y axis
805	(C). Scatterplot demonstrating the IL22+IFNy-IL17-CD4+ T cells per gram on the X axis and
806	normalized expression of L1FLnI_5q32o 1s in colon biopsies on the Y axis (D).
807	
808	Figure S10: Association between colonic LTR19_12p13.31 expression and CD4+ T Cell
809	subsets. Scatterplot demonstrating the IFNy-IL17+CD4+ T cells per gram on the X axis and
810	normalized expression of LTR19_12p13.31 in colon biopsies on the Y axis (A). Scatterplot
811	demonstrating the IFNy+IL17-CD4+ T cells per gram on the X axis and normalized expression
812	of LTR19_12p13.31 in colon biopsies on the Y axis (B). Scatterplot demonstrating the
813	IFNy+IL17+CD4+ T cells per gram on the X axis and normalized expression of
814	LTR19_12p13.31 in colon biopsies on the Y axis (C). Scatterplot demonstrating the IL22+IFNy-
815	IL17-CD4+ T cells per gram on the X axis and normalized expression of LTR19_12p13.31 in
816	colon biopsies on the Y axis (D).
817	
818	Figure S11: Colonic expression of EREs of interest produce negligible correlations with
819	serum IL-6 and LPS. Scatterplots demonstrating serum lipopolysaccharide (LPS)
820	concentrations on the X axis and normalized expression of L1FLnI_1q23.1s (A), L1FLnI_5q32o

821 (B), LTR19\_12p13.31 (C) in colon biopsies on the Y axis. Scatterplots demonstrating serum IL-6

- concentrations on the X axis and normalized expression of L1FLnI\_1q23.1s (D), L1FLnI\_5q32o
  (E), LTR19 12p13.31 (F) in colon biopsies on the Y axis.
- 824

#### 825 Figure S12: HIV-1 status influences endogenous retroelement expression in the PBMC

- 826 fraction. Heatmap demonstrating the normalized per sample abundances of EREs following the
- preprocessing filtering of reads in uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19)
- 828 individuals. ERE reads were filtered to possess at least 2 reads in 10% of the total samples for
- quality assurance (A). Heatmap demonstrating the normalized per sample abundances of EREs
- 830 differentially expressed with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq -1$  between
- uninfected controls (red) (n = 13) and PLWH (blue) (n = 19) gut biopsies. All statistics were
- 832 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default
- 833 parameters for a Benjamini-Hochberg correction (B). PCA plot based solely on ERE abundances
- 834 demonstrate no variance in sample distribution between uninfected controls (red) (n = 13) and
- 835 PLWH (blue) (n = 19) PBMCs (C).
- 836
- 837
- 838
- 839
- 840
- 841
- 842
- 843
- 844

# 845 Supplemental Table

## 846

	Controls	PLWH	P value
Number of study participants	13	19	
Age			
Median (min, max) (years)	33 (23, 54)	33 (22, 58)	0.96
Sex			
Male	8	13	0.72
Female	5	6	
Ethnicity			
Non-Hispanic	11	14	0.67
Hispanic	2	5	
Race			
White/Caucasian	9	15	0.62
Black/African American	2	3	
Asian	2	1	
Men who have sex with men (MSM)			
Yes	1	12	0.003
No	12	7	
Reported intravenous drug use (IDU)*			
Yes	0	4	0.11
No	14	14	
Blood CD4 count			
Median (min, max) (cells/µl)	720 (468,1071)	429 (221, 836)	0.002

Plasma HIV RNA copies/ml

	Median (min, max)	N/A	26000 (2880, 196000)	
	Years since first HIV-1 seropositive test			
	Median (min, max)	N/A	3.5 (0.17, 15.0)	
847	Study participants were selected from a	completed clinica	1 study <sup>53</sup> . Values are shown as median	
848	(range) for continuous measures and nur	mbers for categorie	cal measures. Statistical analyses were	
849	performed using Mann-Whitney test for continuous characteristics and Fishers exact test to			
850	compare categorical characteristics betw	ween control and	PWH groups. *not reported for one	
851	person in PWH cohort. N/A: not applicat	ole.		
852				
853				
854				
855				
856				
857				
858				
859				
860				
861				
862				
863				
864				
865				
866				
867				

868	Research	in	Context

869

870 Evidence before this study

871

- 872 Previous studies have demonstrated that HIV-1 infection alters the physiology of the GI tissues, 873 where it forms quiescent reservoirs. In chronic HIV-1, the sustainment of antiviral immune 874 responses through poorly understood mechanisms likely contributes to pathogenesis and 875 prohibits effective clearance of the viral reservoirs. EREs comprise a substantial portion of the 876 human genome that has been implicated in HIV-1 pathogenesis but remains understudied in 877 comparison to coding genes. Therefore, studying the activity of EREs in tissues such as the GI 878 tract may help further define the physiology of immunopathologies that contribute to HIV-1 879 reservoir persistence. 880 881 Added value of this study 882 883 Colon pinch biopsies from PLWH demonstrate differential expression of 59 EREs when 884 compared to uninfected controls. Of these 59, 3 possess near-significant correlations with viral 885 load. Further analysis into cellular composition of the gut microenvironment demonstrates that 2
- the EREs LTR19\_12p13.31 and L1FLnI\_1q23.1s possess significant associations with immune
- 887 cell phenotypes indicative of localized HIV-1 pathogenesis. Therefore, high expression of
- 888 LTR19\_12p13.31 and L1FLnI\_1q23.1s can function as markers of GI HIV-1 reservoirs, as well

as potentially possess undefined roles in human health.

## 891 Implications of all the available evidence

- 893 Recurrent observations suggest pathophysiological roles for differentially expressed EREs in
- diseased tissues. In HIV-1 infection, EREs can be over expressed due to trans-activation of
- HERV LTRs and shifts in the regulome that permit the expression of typically silent elements.
- 896 However, it has not been established how EREs may be deregulated in the gut where
- 897 immunopathologies persist surrounding viral reservoirs. Correlations between ERE expression
- and cellular composition demonstrate that certain EREs may be indicative of cell type
- abundances thought to drive GI-specific immunopathologies resultant from HIV-1 infection.







